PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
19661247-7	2009	MEASUREMENTS AND MAIN RESULTS: In a cell-free system, acrolein, in concentrations equal to those found in COPD sputum, directly adducted cysteine 319 in the MMP14 hemopexin-like domain and activated MMP14.	Acrolein	54-62	matrix metallopeptidase 14 (membrane-inserted)	Mus musculus	157-162	
19661247-7	2009	MEASUREMENTS AND MAIN RESULTS: In a cell-free system, acrolein, in concentrations equal to those found in COPD sputum, directly adducted cysteine 319 in the MMP14 hemopexin-like domain and activated MMP14.	Acrolein	54-62	matrix metallopeptidase 14 (membrane-inserted)	Mus musculus	199-204	
19661247-10	2009	In mouse lung, acrolein or tobacco smoke increased lung MMP14 activity and protein.	Acrolein	15-23	matrix metallopeptidase 14 (membrane-inserted)	Mus musculus	56-61	
19661247-11	2009	In cells, acrolein-induced MMP14 transcripts were inhibited by an epidermal growth factor receptor (EGFR) neutralizing antibody, EGFR kinase inhibitor, metalloproteinase inhibitor, or mitogen-activated protein kinase (MAPK) 3/2 or MAPK8 inhibitors, but not a MAPK14 inhibitor.	Acrolein	10-18	matrix metallopeptidase 14 (membrane-inserted)	Mus musculus	27-32	
19661247-13	2009	In acrolein-exposed mice or transgenic mice with lung-specific transforming growth factor-alpha (an EGFR ligand) expression, lung MMP14 and MUC5AC levels increased and these effects were inhibited by a EGFR inhibitor, erlotinib.	Acrolein	3-11	matrix metallopeptidase 14 (membrane-inserted)	Mus musculus	130-135	
19661247-14	2009	CONCLUSIONS: Taken together, these findings implicate acrolein-induced MMP14 expression and activity in mucin production in COPD.	Acrolein	54-62	matrix metallopeptidase 14 (membrane-inserted)	Mus musculus	71-76